PCM
MRNA icon

Princeton Capital Management’s Moderna MRNA Stock Holding History

Princeton Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,420
Closed -$1.59M – 123
2024
Q2 		$1.59M Buy
13,420
+913
+7% +$116K 0.52% 35
2024
Q1 		$1.33M Buy
12,507
+752
+6% +$75.8K 0.48% 42
2023
Q4 		$1.17M Sell
11,755
-2,816
-19% -$237K 0.47% 45
2023
Q3 		$1.51M Buy
14,571
+1,503
+12% +$168K 0.69% 36
2023
Q2 		$1.59M Buy
13,068
+331
+3% +$44.2K 0.66% 35
2023
Q1 		$1.96M Sell
12,737
-271
-2% -$44.7K 0.84% 32
2022
Q4 		$2.34M Buy
13,008
+3
+0% +$491 1.04% 30
2022
Q3 		$1.54M Sell
13,005
-520
-4% -$78.9K 0.67% 34
2022
Q2 		$1.93M Buy
13,525
+175
+1% +$25K 0.75% 34
2022
Q1 		$2.3M Buy
13,350
+795
+6% +$134K 0.71% 37
2021
Q4 		$3.19M Buy
12,555
+154
+1% +$45K 0.91% 31
2021
Q3 		$4.77M Buy
12,401
+131
+1% +$48.3K 1.52% 20
2021
Q2 		$2.88M Buy
+12,270
New +$2.19M 0.89% 37

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Princeton Capital Management's MRNA Position: Q3 2024 in Review

Princeton Capital Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 13,420 shares — an estimated $1.59M sold.

Princeton Capital Management first reported a position in MRNA in Q2 2021 and held it in 13 quarters. The position peaked at $4.77M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Princeton Capital Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Princeton Capital Management sold 13,420 Moderna shares in Q3 2024, an estimated $1.59M.
  • Princeton Capital Management first reported a position in Moderna in Q2 2021 and held it in 13 quarters.
  • Princeton Capital Management's Moderna position peaked at $4.77M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Princeton Capital Management's 13F filing for Q3 2024, filed 7 Nov 2024.